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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from
a retrospective multicentric clinical study
Andrea Gallamini, Caterina Stelitano, Roberta Calvi, Monica Bellei, Daniele Mattei, Umberto Vitolo, Fortunato Morabito, Maurizio Martelli,
Ercole Brusamolino, Emilio Iannitto, Francesco Zaja, Sergio Cortelazzo, Luigi Rigacci, Liliana Devizzi, Giuseppe Todeschini,
Gino Santini, Maura Brugiatelli, and Massimo Federico, for the Intergruppo Italiano Linfomi
To assess the prognosis of peripheral
T-cell lymphoma unspecified, we retro-
spectively analyzed 385 cases fulfilling
the criteria defined by the World Health
Organization classification. Factors asso-
ciated with a worse overall survival (OS)
in a univariate analysis were age older
than 60 years (P  .0002), equal to or
more than 2 extranodal sites (P  .0002),
lactic dehydrogenase (LDH) value at nor-
mal levels or above (P < .0001), perfor-
mance status (PS) equal to or more than 2
(P< .0001), stage III or higher (P  .0001),
and bone marrow involvement (P  .0001).
Multivariate analysis showed that age
(relative risk, 1.732; 95% CI, 1.300-2.309;
P < .0001), PS (relative risk, 1.719; 95%
CI, 1.269-2.327, P < .0001), LDH level (rela-
tive risk, 1.905; 95% CI, 1.415-2.564;
P < .0001), and bone marrow involve-
ment (relative risk, 1.454; 95% CI, 1.045-
2.023; P  .026) were factors indepen-
dently predictive for survival. Using these
4 variables we constructed a new prog-
nostic model that singled out 4 groups at
different risk: group 1, no adverse fac-
tors, with 5-year and 10-year OS of 62.3%
and 54.9%, respectively; group 2, one
factor, with a 5-year and 10-year OS of
52.9% and 38.8%, respectively; group 3, 2
factors, with 5-year and 10-year OS of
32.9% and 18.0%, respectively; group 4, 3
or 4 factors, with a 5-year and 10-year OS
of 18.3 and 12.6%, respectively (P < .0001;
log-rank, 66.79). (Blood. 2004;103:
2474-2479)
© 2004 by The American Society of Hematology
Introduction
In Western countries peripheral T-cell non-Hodgkin lymphomas
(PTCLs) account for 15% to 20% of aggressive lymphomas1 and
for 7% to 10% of all the non-Hodgkin lymphomas (NHLs).2,3 They
usually occur in middle-aged to elderly patients, and presenting
features are characterized by a disseminated disease in 68% of the
patients, with systemic symptoms in nearly half of them (45%),
bone marrow (BM) involvement in a quarter (25.8%), and extran-
odal disease in a third (37%). Despite aggressive therapy, the
prognosis is dismal, with more than half the patients dying of
their disease.2
The influence of the immunophenotype on the outcome of
aggressive NHL has long been questioned4,5; in the more recent
literature, however, most authors agree on the adverse prognostic
meaning of the T-cell phenotype per se,3,6-9 regardless of other
well-defined clinical prognostic indexes such as the International
Prognostic Index (IPI).10
In the past, a number of definite entities corresponding to
recognizable subtypes of T-cell neoplasm, such as Lennert lym-
phoma, T-zone lymphoma, pleomorphic T-cell lymphoma, small
and medium-sized, and large-cell T-cell lymphoma, and T-
immunoblastic lymphoma have been described,11 but evidence that
these correspond to distinctive clinicopathologic entities is still
lacking.2,8,9,12 For this reason the recent World Health Organization
(WHO) classification of the hematopoietic and lymphoid neo-
plasms has collected these under the single broad category of
“peripheral T-cell lymphoma, unspecified (PTCL-U).13 The natural
history of PTCL seems to be unchanged by the use of second- and
third-generation chemotherapy regimens8 and 5-year overall sur-
vival (OS) still remains between 25% and 47%.2-3,6-11 Although
high-dose sequential (HDS) chemotherapy followed by autologous
hematopoietic stem cell transplantation (ASCT) has been success-
fully performed in 2 small series of patients,14,15 others16,17 in a
large cohort of high-risk NHL treated with HDS chemotherapy
followed by ASCT have definitely demonstrated no benefit of
autologous bone marrow transplantation in the subset of T-cell
lymphomas.14
To better define the clinical outcome of T-cell lymphomas
grouped within the broad category of PTCL-U as a single entity,
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and to assess a prognostic model specifically devised for patients
with this uncommon disease, the Intergruppo Italiano Linfomi (IIL)
promoted a large, retrospective, collaborative study. Here we report
the results of this study, performed on 385 newly diagnosed
patients followed at participating institutions between January
1989 and December 2001.
Patients and methods
Among 10 315 cases of lymphoma recorded through June 2002 at the IIL
Lymphoma Registry, we selected all cases of PTCL diagnosed between
January 1989 and December 2001. A preliminary working file containing
information on 512 cases, fulfilling all the characteristics of “Peripheral T-
Cell Lymphoma, Unspecified,” was created.
Thereafter we considered eligible for the study all patients with: (1)
histologically confirmed diagnosis of PTCL-U, according to the WHO
classification.13 Distinctive entities, formerly classified as PTCL and
characterized by a definite clinical picture (such as angioimmunoblastic
T-cell lymphoma, anaplastic large-cell lymphoma [ALCL], entheropathy-
associated T-cell lymphoma, nasal-type T-cell lymphoma, or primary
cutaneous T-cell lymphoma), were excluded from the analysis. No cases of
T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, or primary
hepatosplenic T-cell lymphoma were recorded. (2) Proven T-cell phenotype
either by immunohistochemistry, flow cytometry, or rearrangement of
T-cell receptor. Additional criteria for inclusion were (3) availability of a
complete set of clinical data for an accurate clinical staging, including
diagnostic biopsy with immunohistochemistry or flow cytometry (or both),
complete blood count, biochemistry, whole body computed tomography
(TC) scan, or 67Ga scintigraphy, and BM trephine biopsy and (4) a
minimum follow-up of 1 year, with the last observation recorded no more
than 6 months before data collection.
Of 512 cases retrieved from the Registry for the primary working file we
excluded 127 patients for the following reasons: 23 exhibited clinical
characteristics and a histologic description of “nasal-type” T-cell lym-
phoma, 47 for incomplete clinical data, 21 for unproven T-cell phenotype,
and 36 for inadequate follow-up. The participating centers were asked for a
simple set of clinical data including age, sex, complete blood count,
erythrocyte sedimentation rate (ESR), lactic dehydrogenase (LDH) level,
and serum 2-microglobulin level. Ann Arbor stage, IPI, number and sites
of extranodal disease, BM involvement, systemic symptoms, bulky disease,
PS, date of diagnosis, type of treatment, response to therapy, date of
assessment of response, date of relapse, date of last follow-up, status (alive
or deceased), and, if deceased, date and cause of death. Bulky disease was
defined as a mass with the largest diameter greater or equal to 10 cm or, for
the mediastinum only, a mass lager than one third of the chest diameter.
Systemic symptoms were defined, according to Ann Arbor criteria, as
recurrent fever ( 38°C), night sweats, or loss of a more than 10% of
body weight.
Response to treatment was assessed 1 month after the end of induction
therapy by performing all the examinations with pathologic values at
baseline, which concurred to define the stage. Complete remission (CR)
was defined as the disappearance of all clinical evidence of the disease and
the normalization of all laboratory values and radiologic findings that had
been considered abnormal before starting therapy. Partial remission (PR)
was defined as a more than 50% reduction, for at least 1 month, of the
largest dimension of each measurable anatomic site of disease localization.
Nonresponse (NR) was defined as a less than 50% regression of tumor size,
or stable/progressive disease. All the deaths occurring because of disease
progression or related to treatment toxicity were considered as treatment
failures, and the patients were included in the NR group.
Histologic findings
Table 1 lists the different histologic subtypes conforming to the PTCL-U
diagnosis. The most frequent subtype (189 of 385, 49.1%) was character-
ized by a simple cytologic description of the tumor and included a number
of subentities (large cell, large and medium-sized cell, pleomorphic cell,
small cell) differing in cell size and the relative proportion of large or small
cells. Other categories were PTCL-U not otherwise specified (PTCL-U
NOS), T-zone lymphoma, lymphoepithelioid lymphoma (or Lennert lym-
phoma). In 290 cases the T phenotype was proven on immunohistochemical
grounds, in 73 cases by cytofluorimetric assay of a fresh cellular suspen-
sion, and in 22 cases by rearrangement of T-cell receptor.
Treatment strategies
Patients were grouped in 4 main categories (Table 2), according to the
treatment strategy adopted: (1) only supportive care, 7 (2%) of 385; (2)
nonanthracyclin chemotherapy, 32 (8%) of 385; (3) anthracyclin-based
chemotherapy, 302 (78%) of 378; and (4) autologous or allogeneic BM
transplantation as part of a primary treatment, 44 (12%) of 385.
Statistical analysis
All data were analyzed with the Statistical Package for the Social Sciences
(SPSS).18 OS and relapse-free survival (RFS) curves were calculated
according to the Kaplan and Meier method.19 OS was calculated from the
date of diagnosis until death from any cause or date of last contact for living
patients. For patients in CR, RFS was calculated from the date of diagnosis
to the first evidence of relapsing disease. The association between clinical
factors and the probability of attaining CR was evaluated by likelihood ratio
2 test. In cases where the date of the therapy onset was not available, the
survival was calculated from the date of the diagnosis until the date of the
last follow-up or death. RFS was applied only in patients attaining CR and
was calculated from the end of first-line therapy to relapse. The univariate
association between individual clinical features and OS were determined
with the log-rank test.20 Factors independently associated with OS were
identified in multivariate analysis by the Cox proportional hazards regres-
sion model.21 The limit of significance for all analyses was defined as a P
value of .05; 2-sided tests were used in all calculations.
Results
The characteristics of the 385 patients fulfilling the inclusion
criteria and entered into the study are summarized in Table 3.
The median age was 54 years (range, 15-96 years), and there
was a male preponderance, with a male- to-female ratio of 1.83.
Disease extension and frequency of extranodal sites (ENSs) were
suggestive of an aggressive onset: 291 (76.1%) of 385 were in stage
III or IV, and 192 (49.9%) of 385 in stage IV; more than two thirds
(281 of 385, 73%) presented organ involvement. Table 4 shows the
extranodal spread of the disease, with BM being the most frequent
Table 2. Treatment strategies
Treatment No. of cases % of cases
No therapy 7 2
Nonanthracyclin CT 32 8
CT with anthracyclin 302 78
HDS plus ASCT 44 12
CT indicates chemotherapy.
Table 1. Histologic PTCL-U subtypes
Description No. of cases % of cases
PTCL-U NOS 162 42.0
Large cell 71 18.4
Largemedium-sized cell 64 16.6
Pleomorphic cell 31 8.0
Small cell 23 5.9
Lymphoepithelioid 19 4.9
T-zone 15 3.8
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site (118 of 385, 32.2%), followed by spleen (95 of 385, 24.6%),
liver (50 of 385, 12.9%), Waldeyer ring (42 of 385, 10.9%), and
skin (39 of 385, 10.1%).
Bulky disease was present in 58 (15.1%) of 385 patients; mean
hemoglobin value was 12.35 g/dL; (range, 6-17 g/dL); mean
absolute neutrophil count was 5362/L (range, 238-35 520/L),
mean lymphocyte count 2323/L (range, 165-75 072/L); and
mean platelet count 235 345/L (range, 3000-613 000/L). Nearly
half the patients presented with systemic symptoms (175 of 385,
45.5%), and two thirds showed an ambulatory PS (Eastern
Cooperative Oncology Group [ECOG] PS 0-1, 274 of 385, 71.2%);
lactate dehydrogenase (LDH) levels were elevated in one third of
the cases ( 1  normal value, 159 of 350, 45.4%).
IPI scoring was available in 346 (89.9%) of 385 of the patients;
accordingly 98 (28.3%) patients were classified as low risk (0-1),
91 (26.3%) as intermediate-low2; 93 (26.9%) as intermediate-
high,3 and 64 (18.5%) as high risk.4,5
Analysis of response
In 6 of 385 patients the response to therapy was not recorded and in
7 patients no therapy was given; therefore information on 372
patients was available for treatment response. Overall, the CR rate
was 53.2% (198 of 372); PRs were observed in 20.7% (77 of 372)
and failures in 26.1% (97 of 372). In univariate analysis the factors
associated with a lower probability of achieving CR were advanced
stage (III-IV) (odds ratio [OR] 2.781; 95% CI, 1.656-4.671;
P  .0001), the presence of ENSs (OR 2.577; 95% CI, 1.688-
3.935; P  .0001), BM involvement (OR 2.501; 95% CI, 1.580-
3.959; P  .0001), poor PS (OR 2.213; 95% CI, 1.393-3.517;
P  .001), high LDH levels (OR 2.158; 95% CI, 1.397-3.334;
P  .001), age older than 60 years (OR 1.719; 95% CI, 1.129-
2.618; P  .012), and low hemoglobin level (OR 1.708; 95%
CI, 1.018-2.865; P  .042). IPI proved to be of highly significant
prognostic value (P  .0001).
The 5 characteristics that remained independently significant in
multivariate analysis were: poor PS (OR 2.381; 95% CI, 1.141-
4.968; P  .021), the presence of ENSs (OR 2.112 ; 95% CI,
1.106-4.032; P  .023), age older than 60 years (OR 2.144;
95% CI, 1.101-4.176; P  .025), BM involvement (OR 2.169;
95% CI, 1.038-4.532; P .039), and high LDH levels (OR 2.127;
95% CI, 1.018-4.441; P  .045).
Analysis of survival
After a mean follow up of 43.2 months, 229 (59.4%) of 385patients
had died, and the cumulative probability of survival at 5 years
(Figure 1) was 43.0%.
Forty-four percent of the deaths occurred in the first 12 months
and an additional 23% occurred in the following year. The 5-year
and 10-year RFS among patients who achieved CR were 49.5%
and 42.9%, respectively. Factors significantly associated with
prolonged response duration were early stage (P  .00004), ab-
sence of BM involvement (P  .0011), normal serum LDH levels
(P  .0150), good PS (P  .0232), and female sex (P  .0215).
The clinical parameters associated with reduced survival in
univariate analysis are listed in Table 5: age older than 60 years
(P  .0002), 2 or more ENSs (P  .0002), LDH level equal to or
more than normal value (P  .0001), PS equal to or more than 2
Figure 1. OS of 385 PTCL-U patients. Crosses mark censored cases.
Table 3. Clinical and biologic characteristics of the patients
Characteristics
No. of
patients
No. of
patients available %
Age, y 385
60 or younger 234 60.8
Older than 60 151 39.2
Sex
Men 249 385 64.7
Women 136 35.3
ECOG PS 383
0-1 274 71.2
2-4 109 28.3
Ann Arbor stage 385
I-II 92 23.9
III-IV 293 76.1
Systemic symptoms 385
Yes 175 45.4
No 210 54.6
Bulky disease greater than 10 cm 385
Yes 58 15.0
No 327 85.0
No. of ENSs 385
0-1 224 58.2
More than 2 161 41.8
BM involvement 368
Involved 118 32.1
Not involved 250 67.9
LDH level 350
Normal 191 54.6
Higher than normal 159 45.4
IPI 346
1-2 189 54.6
3-4 157 45.4
Hemoglobin level 352
Less than 12 g/dL (men) or
less than 10 g/dL (women) 78 22.1
More than 12 g/dL (men) or
more than 10 g/dL (women) 278 78.9
Table 4. Sites involved in 281 patients with extranodal involvement
Site
No. of
cases
% of
cases
% of all
ENSs
BM 118 30.6 41.9
Spleen 95 24.6 33.8
Liver 50 12.9 17.7
Waldeyer ring 42 10.9 14.9
Skin 39 10.1 13.8
Lung pleura 38 9.8 13.5
Gut 35 9.0 12.4
Bone 18 4.6 6.4
Soft tissues 5 1.2 1.7
Others 54 14.02 19.2
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(P  .0001), advanced disease (stage  III; P  .0001), BM
involvement (P  .0001), 2-microglobulin level (available in 109
of 385 patients) more than 2.7 ng/mL (P  .0231), less than
complete response to the therapy (P  .0001), and IPI (P  .0001).
Systemic symptoms and bulky disease were nonsignificant factors.
Excluding 2-microglobulin, the 8 prognostic factors available
in most patients (324 of 385) were significantly associated with
prognosis in univariate analysis. All these cases were selected for
developing a prognostic model.
Prognostic model
In multivariate analysis the factors that turned out to correlate
significantly with survival were age (P  .0001; relative risk,
1.732; 95% CI 1.300-2.309), PS (P  .0001; relative risk,
1.719; 95% CI 1.269-2.327), LDH level (P  .0001; relative
risk, 1.905; 95% CI  1.415-2.564), and BM involvement
(P  .026; relative risk, 1.454; 95% CI 1.045-2.023; Table 6).
Because the relative risk associated with each of the 4 factors
was comparable, we constructed a new prognostic model by
combining these prognostic variables in the following way: group
1, no adverse factors; group 2, 1 factor; group 3, 2 factors; and
group 4, 3 or 4 factors. This novel Prognostic Index for PTCL-U
(PIT) model was able to efficiently identify 4 groups of patients
with different outcomes (Figure 2; P  .0001; log-rank, 66.79).
For the 64 patients in group 1 the 5-year and 10-year survival
rates were 62.3% and 54.9%, respectively; for the 108 patients in
group 2, 52.9% and 38.8%; for the 83 patients in group 3, 32.9%
and 18.0%; and for the 67 patients in group 4, 18.3% and 12.6%.
In the same cohort of 324 patients, the IPI predictive model,
developed for aggressive B-cell NHL, was able to identify 4
categories of patients with different prognoses: low in 91 patients,
intermediate-low in 86 patients, intermediate-high in 85 patients,
and high in 62 patients. The 5-year and 10-year survival rates were
58.94% and 50.0%, respectively, in the low-risk group; 45.6% and
32.3% in the intermediate-low risk group; 39.7% and 29.8% in the
intermediate-high risk group; 18.3% and 9.15% in the high risk
group (P  .0001, log-rank 53.80; Figure 3).
Considering a simplified 2-class model both for IPI and PIT we
found that 278 (86.3%) of 322 patients were allocated in the same
risk group using both indexes; the latter, however, showed a
superior predictive power (log-rank 47.48 versus 28.91; Figure 4).
Discussion
Peripheral T-cell lymphomas are a heterogeneous group of neo-
plasms presenting as advanced disease and are characterized by
widespread dissemination, aggressive behavior, and a very poor
outcome. In the literature so far published the 5-year OS ranges
between 25% and 45%.2,3,7-10,14,22 However, the meta-analysis of
the prognosis of these neoplasms from the retrospective clinical
reviews is somewhat cumbersome, due to the differences of the
histologic subtypes accrued and of different follow-up times.
Moreover, in 1994 the Revised European-American Lymphoma
(REAL) classification and in 1997 the WHO classification intro-
duced a substantial modification in the classification of these
disorders. A number of different T-cell peripheral lymphomas, once
considered as distinctive entities, are now collectively referred to as
PTCL-U. Conversely, other lymphoma subtypes such as ALCL,
formerly classified as peripheral T-cell lymphoma and character-
ized by a relatively good prognosis, were singled out, and
considered separately. For example, in the largest series published
so far on the prognosis of PTCL-U, Gisselbrecht et al8 report a
5-year OS for “peripheral T-cell lymphoma” of 41%, but this value
drops to 31% on withdrawal from the analysis of ALCL.
For these reasons we undertook a large, multicenter, retrospec-
tive analysis with the main end point of studying the prognosis of
Table 5. Clinical parameters influencing survival in univariate
analysis
Parameter Cut-off value P
Age, y Older than 60 .0002
ECOG PS 2 or higher  .0001
Stage III or higher .0001
LDH level More than 1 normal value  .0001
ENSs 2 or more .0002
IPI L, I-L, I-H, H  .0001
BM Infiltrated .0001
Response to CT CR vs PR vs NR  .0001
L indicates low; I-L, intermediate-low; I-H, intermediate-high; H, high.
Table 6. Clinical parameters influencing survival in multivariate
analysis
Parameter
Significance,
P
Relative risk
(exp. B)
95% CI,
low
95% CI,
high
Age  .0001 1.732 1.300 2.309
PS  .0001 1.719 1.269 2.327
LDH level  .0001 1.905 1.415 2.564
BM attainment .026 1.454 1.405 2.023
exp. B indicates survival probability A vs B.
Figure 2. OS according to the proposed Prognostic Index for PTCL-U patients
(PIT). Crosses mark censored cases.
Figure 3. OS according to IPI. Crosses mark censored cases.
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PTCL-U patients who were enrolled in the IIL clinical trials during
a period of more than a decade. This is, as far as we know, the
largest clinical retrospective review on the prognosis of this
lymphoma subset. After withdrawal of cases not fulfilling the
inclusion criteria, we were able to enroll 385 patients affected by
PTCL-U, as defined by the WHO classification.13 According to
authors, PTCL-U category is an “empty basket” containing several
histologic subtypes, characterized by a prevalent nodal presenta-
tion and an aggressive but nonspecific clinical behavior. Even if not
all cases had a systematic histologic review, we believe that the
detailed histopathologic picture, the concurrent immunophenotype,
and the exclusion of a number of well-defined clinicopathologic
entities, could have further reduced the inclusion of non PTCL-U
lymphomas in our series.
The 5-year and the 10-year OS of the patients enrolled in the
present study (43.03% and 33.50%, respectively) fit in the upper
limit of the range reported in the literature. This may be because of
the median age, up to 10 years younger than the one reported in
other series,8-10,22 and the large predominance of patients with
ambulatory PS (PS 0-1, 274 of 382, 71.7%). Both differences could
partially reflect a selection of the patients fitting the inclusion
criteria for entering into the clinical trials. Finally, unlike other
retrospective studies, the present study does not encompass subsets
of T-cell lymphomas with a very poor prognosis such as nasal-type
T-cell lymphoma and enteropathy-associated T-cell lymphoma.
At this writing, 229 of 385 patients have died, mostly because of
disease progression or relapse. The risk of death was higher in the
first 2 years since diagnosis and decreased over time; although a
true plateau was never reached, 44.1% and 67.2% of the deaths
were recorded within the first 12 and 24 months, respectively. This
pattern of the survival curve (Figure 1) seems also to demonstrate
that the therapy was unable to change the course of the disease
whatever the strategy chosen; however, the survival of patients
attaining CR was significantly longer. High-dose chemotherapy
followed by autologous BM transplantation was performed in 44
(11.8%) of 372 patients and failed to show any advantage over
standard therapy in prolonging survival (P  .2; data not shown)
This result, in keeping with Rodriguez data,17 is not surprising, if
one considers the low overall response rate to therapy (53.2%) that
we observed in our study, without statistical differences among the
3 therapeutic strategies (P  .6), and the very aggressive behavior
of these neoplasms. However, we are fully aware that no definite
conclusions regarding the role of the therapy can be drawn from a
retrospective clinical trial with an accrual time spanning more than
a decade.
Several studies have been done to assess the contributions of a
number of clinical factors to the prognosis. IPI seems to work as
well in peripheral T-cell lymphomas as in diffuse large-cell
lymphomas8-10,14; however, besides IPI, systemic symptoms and
BM infiltration have been found to correlate with prognosis in a
single study.9
The cytology of the neoplastic cell has long been debated as a
prognostic factor. In the REAL classification 3 morphologic
variants have been proposed: medium-sized cells, mixed medium
and large cells, and large cells,12 but because of lack of reproducibil-
ity these provisional entities were no longer recognized in the
WHO classification. Applying the updated Kiel classification,23
Ascani et al,2 Noorduyn et al,24 and Richards and Stansfield25 were
unable to find any survival difference between low- and high-grade
histologic forms, whereas Rudiger et al22 found that the number of
transformed blasts in 10 random high-power fields was prognosti-
cally relevant.
Another aim of this study was to check the value of the
preexisting prognostic models and to eventually propose a new
system to evaluate the outcome of PTCL-U. As in other aggressive
lymphomas IPI was able to identify subsets of patients with
different prognoses, but in multivariate analysis only 3 of 5
parameters retained their prognostic significance in our study. The
extension of the disease (staging) and the presence of ENSs were
no longer significant, probably because the disease per se is
characterized, in more than two thirds of the patients, by a
presentation in advanced stage and in 2 or more ENSs. BM
involvement has been associated with a poor response to therapy
and a shorter survival in diffuse large-cell B lymphomas23,26; in
PTCL-U it occurs in 20% to 40% of the cases27 and seems to
worsen the prognosis.2 In the present study we observed a BM
involvement in a similar proportion of cases, and we confirmed the
resulting negative impact on survival. This effect occurred indepen-
dently from other IPI prognostic factors, probably because of a
more pronounced tendency of the tumor to spread. Of the
remaining 3 factors prognostically significant in multivariate
analysis, 2 are host-related (age, PS) and the third (elevated LDH
levels) has been considered a marker of increased cell turnover.28
On the basis of these findings we propose a new prognostic
model for PTCL-U, which we have called PIT (Prognostic Index
for PTCL-U), based on these 4 simple clinical variables: age, PS,
LDH level, and BM involvement. PIT seems to differ from IPI
because in the former the 2 IPI factors based on the extension of the
disease (stage and ENSs) do not seem to work with same efficacy.
Conversely, of the 2 PIT factors related to the biology of the tumor
(BM involvement and LDH level), only one (LDH level) has a
prognostic role in IPI.
The PIT model was able to identify 4 classes of patients with
different outcomes, with an overall superior predictive capacity as
compared to IPI (log-rank, 66.79 versus 55.94). The same holds
true considering a simplified 2-class model obtained by grouping
the 4 prognostic classes of IPI and PIT in 2 risk categories: the first
containing class 1 and 2 and the second containing class 3 and 4.
Simplified 2-class PIT fared better than simplified 2-class IPI
(log-rank, 49.36 versus 30.23; Figure 4).
In conclusion, in addition to better defining risk classification in
respect to IPI, the proposed model has shown that nearly half the
patients affected by PTCL-U (classified in groups 3 and 4) had a
very dismal prognosis, with a 5-year survival probability of only
26.81%. For these patients a new therapeutic strategy (eg, monoclo-
nal antibodies associated with ASCT or allo-BM transplantation)
should be explored.
Figure 4. OS according to 2-class, simplified, PIT. Crosses mark censored cases.
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Appendix
Participating institutions and principal investigators of the Intergruppo
Italiano Linfomi on peripheral T-cell lymphoma include the following: S.C.
Ematologia, Azienda ospedaliera S. Croce e Carle, Cuneo (A. Gallamini, D.
Mattei, R. Calvi); S.C. Ematologia, Azienda ospedaliera S. Giovanni
Battista, Torino (E. Gallo, U. Vitolo); Cattedra di Ematologia Universita`
degli studi di Torino (M. Boccadoro, C. Tarella, M. Ladetto); Divisione di
Onco-Ematologia, IRCS Candiolo, Torino (M. Aglietta, D. Rota Scala-
brini); S.C. Medicina, Ospedale di Biella (S. Fontana, A. Tonso); S.C.
Medicina, Ospedale di Asti (E. Scassa, A. Ciravegna, R. Frieri); Cattedra di
Clinica Medica Universita` Piemonte Orientale (G. L. Gaidano); Divisione
di Oncologia Medica C Istituto Nazionale Tumori (A. M. Gianni, L.
Devizzi); Cattedra di Ematologia, Ospedale Maggiore, IRCCS, Milano
(A. T. Maiolo, L. Baldini); Divisione di Ematologia, Ospedali Riuniti di
Bergamo (T. Barbui, S. Cortellazzo); U.SD Ematologia, Spedali Civili
Brescia (G. Rossi, E. Tucci); Divisione di Ematologia IRCCS Policlinico S.
Matteo, Pavia (M. Lazzarino, E. Brusamolino); Cattedra di Medicina
Interna, Universita` di Pavia, IRCCS Policlinico S. Matteo, Pavia (P. Gobbi,
M. Ghirardelli); Dipartimento di Medicina Clinica e Sperimentale, Sezione
di Ematologia, Universita` di Verona (G. Pizzolo, G. Todeschini, F.
Benedetti); Dipartimento di Medicina Clinica e Sperimentale, Universita` di
Padova (G. Semenzato, R. Zambello) Divisione di Ematologia, Ospedale
Regionale Bolzano (P. Coser, G. Quaini); Cattedra di Ematologia, Univer-
sita` di Udine (R. Fanin, F. Zaja); Divisione Medica Onco-Ematologica
Ospedale Civile, Piacenza (L. Cavanna, R. Berte`); Servizio di Ematologia
Arcispedale S. Maria Nuova Reggio Emilia (L. Gugliotta, F. Merli);
Cattedra di Ematologia, Universita` di Modena (G. Torelli);Cattedra di
Oncologia Medica, Universita` di Modena e Reggio Emilia (M. Federico, M.
Bellei); Cattedra di Medicina Interna, Universita` di Modena e Reggio
Emilia (S. Sacchi, G. Longo); Cattedra di Ematologia Istituto Seragnoli
Universita` di Bologna (M. Baccarani, P.L. Zinzani); Divisione di Ematolo-
gia 1° Ospedale S. Martino, Genova (G. Santini, M. Congiu); Divisione di
Ematologia Universita` di Pisa Ospedale S. Chiara, Pisa (M. Petrini,
F.Caracciolo); Cattedra di Ematologia, Policlinico Careggi, Universita` di
Firenze (A. Bosi, L. Rigacci); Cattedra di Clinica Medica, Universita` di
Ancona (P. Leoni, A. Olivieri); Cattedra di Clinica Medica, Policlinico
Monteluce, Perugia (F. Grignani, M. Liberati); -Dipartimento di Biotecnolo-
gie Cellulari ed Ematologia Universita` la Sapienza, Roma (F. Mandelli, M.
Martelli); Dipartimento di Oncologia ed Ematologia Ospedale di Pescara
(M. Fioritoni F. Angrilli); U.O. Medicina Istituto Oncologico, Bari (G.
Colucci, E. Naglieri); -Divisione di Ematologia, Ospedale A. Perrino,
Brindisi (G. Quarta); Divisione di Ematologia IRCCS casa del Sollievo e
della Sofferenza, S. Giovanni Rotondo (A. Carella, M. Dell’Olio); Diparti-
mento di Onco.Ematologia, Az. Ospedaliera Bianchi-Melacrino-Morelli,
Reggio Calabria (C. Stelitano, F. Morabito); -Divisione di Ematologia
Azienda Ospedaliera Papardo Messina (M. Brugiatelli); -Divisione di
Ematologia Ospedale Cervello Palermo (S. Mirto C. Patti); Dipartimento di
Ematologia, Oncologia e TMO Cattedra di Ematologia Universita` di
Palermo (G. Mariani, E. Iannitto); Divisione di Ematologia Ospedale
Businco Cagliari (E. Angelucci G. Cabras).
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